Author Archives: William Looney

From Cyprus to Cambridge: The Rise of Anna Protopapas, Millennium Takeda's New President

Takeda’s Oncology Taskmaster Millennium Takeda’s new president, Anna Protopapas, explains to Pharm exec’s William Looney the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease. PE: The ascent to the “c suite” is not exclusively the result of hard work. Culture, […]
Posted in Global, Strategy | Tagged , , , , | Leave a comment

Time for Russia to Get Serious about Biopharma

Back in 1980, the biotech industry did not exist. There was little difference between the means of production in Western markets and the socialist planned economies embodied by Russia – medicines, still a low-tech purchase, played a modest role in the delivery of health care in both sectors. What happened in the ensuing decades has […]
Posted in Biotech, Emerging Markets, Europe, Global, Strategy | Tagged , , , | 1 Comment

Engage, But Gently: More Top Line Thoughts on 2014

More Top Line Thoughts on 2014:  Engage, but Gently Two weeks in and the New Year already seems old.  Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets – forward and backward – over […]
Posted in Op-Ed, Strategy | Tagged , , , , , , , | Leave a comment

The Pulsing Pharmaceutical: Bioelectronics

GSK Lights a Spark around Bioelectronics Dominating the frontier of medicines discovery is a simple, endlessly challenging question: if not a drug, then what?  Industry science has evolved from the chemical roots of the small molecule to the biologics synthesized from living organisms, but the delivery mechanism – pill or injectable – is basically the […]
Posted in Global, R&D, Technology | Tagged , , , , | 1 Comment

Fred Hassan: More Musings on the Biopharma Learning Curve

Hindsight can be a great teacher – but only if you have the self-awareness needed to adapt those learnings to the next business challenge, whose rough edges are by definition almost always “non-recurring.” In other words, because the circumstances of any setback are unique, the astute manager knows that recovery depends on recognizing that the […]
Posted in healthcare, leadership, People, R&D, Sales, Strategy | Tagged , , , , , | 2 Comments
  • Categories

  • Meta